Literature DB >> 1727487

Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.

J P Moore1, J A McKeating, Y X Huang, A Ashkenazi, D D Ho.   

Abstract

Primary isolates of human immunodeficiency virus type 1 (HIV-1) are much less sensitive to neutralization by soluble CD4 (sCD4) and sCD4-immunoglobulin (Ig) chimeras (CD4-IgG) than are HIV-1 strains adapted to growth in cell culture. We demonstrated that there are significant reductions (10- to 30-fold) in the binding of sCD4 and CD4-IgG to intact virions of five primary isolates compared with sCD4-sensitive, cell culture-adapted isolates RF and IIIB. However, soluble envelope glycoproteins (gp120) derived from the primary isolate virions, directly by detergent solubilization or indirectly by recombinant DNA technology, differed in affinity from RF and IIIB gp120 by only one- to threefold. The reduced binding of sCD4 to these primary isolate virions must therefore be a consequence of the tertiary or quaternary structure of the envelope glycoproteins in their native, oligomeric form on the viral surface. In addition, the rate and extent of sCD4-induced gp120 shedding from these primary isolates was lower than that from RF. We suggest that reduced sCD4 binding and increased gp120 retention together account for the relative resistance of these primary isolates to neutralization by sCD4 and CD4-IgG and that virions of different HIV-1 isolates vary both in the mechanism of sCD4 binding and in subsequent conformational changes in their envelope glycoproteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727487      PMCID: PMC238280     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1.

Authors:  R Kirsh; T K Hart; H Ellens; J Miller; S A Petteway; D M Lambert; J Leary; P J Bugelski
Journal:  AIDS Res Hum Retroviruses       Date:  1990-10       Impact factor: 2.205

2.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.

Authors:  U Olshevsky; E Helseth; C Furman; J Li; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

3.  The human immunodeficiency virus type 1 envelope glycoprotein precursor acquires aberrant intermolecular disulfide bonds that may prevent normal proteolytic processing.

Authors:  R J Owens; R W Compans
Journal:  Virology       Date:  1990-12       Impact factor: 3.616

4.  A soluble CD4 protein selectively inhibits HIV replication and syncytium formation.

Authors:  R E Hussey; N E Richardson; M Kowalski; N R Brown; H C Chang; R F Siliciano; T Dorfman; B Walker; J Sodroski; E L Reinherz
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

5.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

6.  Loss of envelope antigens of HTLV-III/LAV, a factor in AIDS pathogenesis?

Authors:  H R Gelderblom; H Reupke; G Pauli
Journal:  Lancet       Date:  1985-11-02       Impact factor: 79.321

7.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4.

Authors:  J P Moore; J A McKeating; R A Weiss; Q J Sattentau
Journal:  Science       Date:  1990-11-23       Impact factor: 47.728

8.  The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.

Authors:  J O Kahn; J D Allan; T L Hodges; L D Kaplan; C J Arri; H F Fitch; A E Izu; J Mordenti; J E Sherwin; J E Groopman
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

9.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.

Authors:  J P Moore; J A McKeating; W A Norton; Q J Sattentau
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more
  143 in total

1.  Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells.

Authors:  D Schenten; L Marcon; G B Karlsson; C Parolin; T Kodama; N Gerard; J Sodroski
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Authors:  S W Barnett; S Lu; I Srivastava; S Cherpelis; A Gettie; J Blanchard; S Wang; I Mboudjeka; L Leung; Y Lian; A Fong; C Buckner; A Ly; S Hilt; J Ulmer; C T Wild; J R Mascola; L Stamatatos
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  HIV-1 envelope induces activation of caspase-3 and cleavage of focal adhesion kinase in primary human CD4(+) T cells.

Authors:  C Cicala; J Arthos; A Rubbert; S Selig; K Wildt; O J Cohen; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 5.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

6.  A chimeric protein of simian immunodeficiency virus envelope glycoprotein gp140 and Escherichia coli aspartate transcarbamoylase.

Authors:  Bing Chen; Yifan Cheng; Lesley Calder; Stephen C Harrison; Ellis L Reinherz; John J Skehel; Don C Wiley
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate.

Authors:  F C Verrier; P Charneau; R Altmeyer; S Laurent; A M Borman; M Girard
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

8.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.

Authors:  W A O'Brien; S H Mao; Y Cao; J P Moore
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.